TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04029285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: The exergaming group played six IREX® exergames. Those in the TGB group performed exercises that were matched to the IREX® exergames for: movement patterns required, physiological demands, sequence, duration and mode of exercise by adopting open and closed kinetic chain movements, in the same range and loading, across both groups. Each IREX® exergame was played for two minutes and was repeated three times within a session. TGB exercise was conducted in sets of two minutes duration, repeated three times within a session. In both groups participants were given rest periods of 10 to 30 seconds, or longer, if required, between exergames or TGB exercise sets.

Intervention type: OTHER
Group type: OTHER
Intervention: Exergaming
Description: The exergaming group played six IREX® exergames. Those in the TGB group performed exercises that were matched to the IREX® exergames for: movement patterns required, physiological demands, sequence, duration and mode of exercise by adopting open and closed kinetic chain movements, in the same range and loading, across both groups. Each IREX® exergame was played for two minutes and was repeated three times within a session. TGB exercise was conducted in sets of two minutes duration, repeated three times within a session. In both groups participants were given rest periods of 10 to 30 seconds, or longer, if required, between exergames or TGB exercise sets.
Study: NCT04765891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positional release therapy
Description: Positional release therapy was administered in the upper trapezius muscle. The muscle was placed in a shortened position with light pressure and held for 90 seconds per treatment location.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Massage
Description: Participants underwent a petrissage type massage for 5 minutes at the site of the trigger point in the upper trapezius.
Study: NCT03769519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ARICA
Description: Personalized ARICA (AdheRence to Inhaled Corticosteroids in Asthma) intervention package.
Study: NCT01470326

Intervention type: DRUG
Intervention: Bazedoxifene
Description: For adults, take 1 tablet (20 mg of the active ingredient) at a time, once a day.
Study: NCT03311243

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non surgical periodontal therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical periodontal therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemical plaque control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemical plaque control
Study: NCT03345784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiation therapy
Study: NCT02399176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Subjects assume 10 physical postures for 30 seconds each
Study: NCT00768456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5 %
Description: Local Infiltration with Ropivacaine 0.5 %

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic NaCl
Description: Local Infiltration with NaCl
Study: NCT01834911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrabenazine withdrawal
Description: Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently on the drug. Patients will be examined via Stroop test in the OFF state. Two doses of 12.5 mg tetrabenazine will be introduced, spaced 3 hours apart. Stroop test will be performed 6 hours after initial OFF Stroop test.
Study: NCT02819804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03060096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Severe Anxiety/depression: High Intensity Stepped Care
Description: The stepped-care Telehealth high intensity intervention is tailored to participants with severe anxiety and depression. Ppts randomized to this group will have 12 weekly psychotherapy sessions delivered by phone with a licensed therapist. Participants will also receive a CBT (cognitive behavioral therapy) workbook including daily exercises to supplement understanding.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Anxiety/depression: Low Intensity Stepped care
Description: The stepped care Telehealth low intensity intervention is tailored to participants with moderate anxiety and depression. Ppts randomized to this group will receive a self-guided CBT workbook and biweekly (every 2 weeks) check-in calls from a research staff person to assess changes in symptom severity and need for treatment/support.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care Control
Description: Participants with moderate to severe anxiety/depression that are randomized to Enhanced Usual Care Control (EUC) will receive information about referrals/resources in their local area (support groups, mental health providers), NCI materials (Facing Forward: Life after Cancer Treatment, self-help workbooks, copy of the CBT (cognitive behavioral therapy) workbook on completion of the study.
Study: NCT03591211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong Training
Description: Eight-Section Brocades; participants were trained individually.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Cognitive Training of Memory and Executive Function with Activities requiring Mobilization
Study: NCT01512238

Intervention type: OTHER
Intervention: Pharmaceutical care
Description: Information about medicine, sideeffect, adherence
Study: NCT03330301

Intervention type: OTHER
Intervention: D-tect
Description: 1. This study is based on a unique Danish social experiment that took place during a well-defined period between 1937 and December 1985, when it was mandatory to fortify all margarine with vitamin D (1.25 μg/100 g). This well-defined vitamin D fortification period makes it possible to investigate the impact of fetal exposure to extra vitamin D from food fortification on the risk of developing diseases later on. This study is possible due not only to the well-defined adjacent time window but also to the complete registration of every citizen via a civil registration number. This number can be linked, on an individual level, to Danish birth, patient and medical registries; social and ethnic registries; and clinical and other large databases~2. Case-cohort study: vitamin D measurements from dried blood spots and the risk of diseases later on

Intervention type: OTHER
Intervention: D-tect
Description: 1. This study is based on a unique Danish social experiment that took place during a well-defined period between 1937 and December 1985, when it was mandatory to fortify all margarine with vitamin D (1.25 μg/100 g). This well-defined vitamin D fortification period makes it possible to investigate the impact of fetal exposure to extra vitamin D from food fortification on the risk of developing diseases later on. This study is possible due not only to the well-defined adjacent time window but also to the complete registration of every citizen via a civil registration number. This number can be linked, on an individual level, to Danish birth, patient and medical registries; social and ethnic registries; and clinical and other large databases~2. Case-cohort study: vitamin D measurements from dried blood spots and the risk of diseases later on
Study: NCT01821118

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ponezumab
Description: Infusion of Ponezumab (Day 1=10mg/kg; Day 30 and Day 60 dose = 7.5mg/kg) or placebo (saline); administered via infusion for a total infusion time of 20 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (saline)- given via infusion total infusion time of 20 minutes
Study: NCT02202941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procalcitonin guided treatment
Description: Patients who will be randomized to arm will receive antibiotics therapy based on procalcitonin measurement on day 1, 3, 5, 7, 9, 11 and 13.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Patients who will be randomized to this arm will receive antibiotic therapy based on conventional practice.
Study: NCT02350140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text messaging from beginning
Description: Registered women will then receive up to 14 text messages as follows: weeks 28, 30, 32, 34, 36, 38, 39, and 40 during the third trimester of pregnancy; weeks 1, 2, 3, 4, 5, and 6 after delivery.Participants at facilities receiving TextIT will have the option to call or send text messages to a designated clinic phone, to which a clinic nurse will respond. Participants will also have an option to request a call from the clinic by sending a free call back text message to the designated clinic phone at any time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text messaging after 6 months of control
Description: After six months of standard care, women at control clinics will be registered to receive the text messaging intervention with up to 14 text messages as follows: weeks 28, 30, 32, 34, 36, 38, 39, and 40 during the third trimester of pregnancy; weeks 1, 2, 3, 4, 5, and 6 after delivery.
Study: NCT03077841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation
Description: Undergo hypofractionated partial breast irradiation

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Partial Breast Irradiation
Description: Undergo hypofractionated partial breast irradiation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02895893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP Smart
Description: Men who have sex with men and already prescribed and taking oral PrEP will use an application on their smart phone for 4 weeks.
Study: NCT00439517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UFOX + Cetuximab
Description: * Cetuximab infusion (400 mg/m\^2 on day 1 of cycle 1 and 250 mg/m\^2 at each subsequent day 1, as well as on days 8, 15 and 22)~* Oxaliplatin infusion (85mg/m\^2) on days 1 and 15 (every 2 weeks)~* Oral UFT® (250mg/m\^2 tegafur + 560 mg/m\^2 uracil in 3 daily doses rounded to the nearest number of whole capsules) on days 1-21~* Oral Folinic Acid (90 mg in 3 daily divided doses) on days 1-21

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX4 + Cetuximab
Description: * Cetuximab infusion (400 mg/m\^2 on day 1 of cycle 1 and 250 mg/m\^2 at each subsequent day 1, as well as on days 8, 15 and 22)~* Oxaliplatin infusion (85 mg/m\^2) on days 1 and 15 (every 2 weeks)~* 5-FU bolus + infusions (400 mg/m\^2) on days 1, 2, 15 and 16~* Folinic Acid infusions (200 mg/m\^2) on days 1, 2, 15 and 16
Study: NCT02224560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 10 or 20 mg/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 10 or 20 mg/kg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Placebo was presented as an oral solution containing 0 mg/mL CBD in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
Study: NCT00988728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 900435 (Org 25935)
Description: Oral tablets, containing 8 mg of active substance, two tablets (i.e. 16 mg) to be taken twice daily in the morning after breakfast and in the evening after dinner during 4 weeks.~Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with SCH 900435 plus 1 capsule with placebo per day).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral capsules and tablets containing excipients only.~Because of the double-dummy design, subjects will be administered one capsule in the evening, plus two tablets in the morning after breakfast and two tablets after dinner.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules and tablets containing excipients only.~Because of the double-dummy design, subjects will be administered one capsule in the evening, plus two tablets in the morning after breakfast and two tablets after dinner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral capsules and tablets containing excipients only.~Because of the double-dummy design, subjects will be administered one capsule in the evening, plus two tablets in the morning after breakfast and two tablets after dinner.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Oral capsules containing 15 mg of active substance, one capsule to be taken once daily after dinner for four weeks.~Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with placebo plus 1 capsule with olanzapine per day).
Study: NCT02198378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEOPA and paracetamol
Description: The patient will be equipped with a facemask after he/she has been informed. The facemask is adapted to the patient. The patient breathes normally in the mask which is held in place by a member of the SMUR team who has received previous training in use of MEOPA. The gas flow received by the patient is adapted to his/her ventilation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Bolus of 2 mg intravenously if EN = 4 or 5 and 3 mg bolus if EN\> 6 followed by reinjection of 2mg every 5 minutes until effective analgesia.
Study: NCT02566421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted Therapy
Description: Receive treatment based on genomic sequencing
Study: NCT02261701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early mobilization
Description: Early mobilization, collar´n cuff 4 weeks post surgery and after this light exercises start and no further bandage.

Intervention type: OTHER
Group type: OTHER
Intervention: Post surgery shoulder lock
Description: Post surgery: Shoulder lock with abduction cushion, additionally 3 weeks with collar´n cuff, and after this period light exercises are allowed and nu further bandage.
Study: NCT00560001

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MD.2 Medication Dispenser
Description: For those subjects receiving an MD.2 Medication Dispenser, the machine organizes medications and provides verbal and auditory explicit reminders for individuals to take their medications. At the scheduled time, the patient gets a series of reminders. The patient is then expected to push a single button to dispense a pre-filled medication cup. An automatic record is kept of the subject's medication adherence. Interviewer-administered surveys of the Geriatric Depression Scale, SF-12 Health Status Inventory, self-reported medication compliance and recent hospitalizations and emergency room visits will be given. Caregivers will complete the Caregiver Burden Interview.

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: MD.2 Medication Dispenser
Description: For those subjects receiving an MD.2 Medication Dispenser, the machine organizes medications and provides verbal and auditory explicit reminders for individuals to take their medications. At the scheduled time, the patient gets a series of reminders. The patient is then expected to push a single button to dispense a pre-filled medication cup. An automatic record is kept of the subject's medication adherence. Interviewer-administered surveys of the Geriatric Depression Scale, SF-12 Health Status Inventory, self-reported medication compliance and recent hospitalizations and emergency room visits will be given. Caregivers will complete the Caregiver Burden Interview.
Study: NCT03254758

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell
Description: Phase1 The dose of AD-MSCs are escalated from low to mid and high step by step. Each administration is one time via intravenous infusion for one hour.~Phase2 The recommended dose of ADR-001 is administrated once a week 4 times. The administration route and time is same method with Phase 1.
Study: NCT00272311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Dosage
Study: NCT00477386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Decitabine dose will be escalated as follows.~Dose level 1: 10mg/m2 IV QD X 5 days Dose level 2: 20mg/m2 IV QD X 5 days Dose level -1: Carboplatin AUC 4.
Study: NCT02052388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daptomycin
Description: Active Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brilacidin
Description: Experimental Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brilacidin
Description: Experimental Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brilacidin
Description: Experimental Drug
Study: NCT01308437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wosulin (N or 70/30 with R)
Description: Basal bolus conventional Insulin viz. Wosulin (N or 70/30 with R) to be injected subcutaneously.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Novolin® (N or 70/30 with R)
Description: Basal bolus conventional Insulin viz. Novolin® (N or 70/30 with R) to be injected subcutaneously.
Study: NCT04067817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norepinephrine
Description: patient who was received the treatment of norepinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: patient who was received the treatment of phenylephrine
Study: NCT02871934

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SLCO1B1 Genotype
Description: Polymerase chain reaction (PCR) assay for SLCO1B1 rs4149056, with possible results T/T, T/C, or C/C.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SLCO1B1 Genotype
Description: Polymerase chain reaction (PCR) assay for SLCO1B1 rs4149056, with possible results T/T, T/C, or C/C.
Study: NCT04000633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2%
Description: the patients of this group will recieve nebulization of 5 ml of 2% lidocaine prior to induction of general anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline
Study: NCT00929695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: immunosuppressive drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: immunosuppressive drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: immunosuppressive drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: immunosuppressive drug

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT04616456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]PBR06
Description: PET radiopharmaceutical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verdiperstat
Description: verdiperstat targets microglial inflammation in the brain
Study: NCT00318643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: intravesical administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: intravesical administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: intravesical administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: intravesical administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: intravesical administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemophase
Description: intravesical administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemophase
Description: intravesical administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemophase
Description: intravesical administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemophase
Description: intravesical administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemophase
Description: intravesical administration